Acumen Pharmaceuticals, Inc.
NASDAQ:ABOSBiotechnology
+$0.02 today
- Market cap
- $165.63M
- Beta
- 0.35
- P/E (TTM)
- -1.3
- EPS (TTM)
- -$1.79
Volume 0.81M
Average 0.40M
Balance Sheet
Inspect the capital base behind the business.
Assets
$122.83M
FY 2025 · Annual
-48.6% YoYLiabilities
$52.40M
FY 2025 · Annual
-8.3% YoYEquity
$70.43M
FY 2025 · Annual
-61.3% YoYBalance Sheet
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | 122.16M | 130.1M | 66.89M | 35.63M | 53.99M |
| Short-term Investments | 72.08M | 47.5M | 176.64M | 135.93M | 62.88M |
| Net Receivables | 0 | 0 | 225K | 0 | 625K |
| Inventory | 0 | 199K | 0 | 159K | 0 |
| Other Current Assets | 2.83M | 1.42M | 1.96M | 5.73M | 4.16M |
| Total Current Assets | 198.66M | 180.33M | 246.62M | 178.31M | 122.25M |
| Property, Plant & Equipment (Net) | 36K | 270K | 503K | 339K | 243K |
| Goodwill | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 169K | 0 | 29K |
| Long-term Investments | 31.62M | 15.84M | 62.55M | 59.97M | 0 |
| Tax Assets | 0 | 0 | 0 | 0 | 163K |
| Other Non-current Assets | 14K | 151K | 285K | 379K | 146K |
| Total Non-current Assets | 31.67M | 16.26M | 63.51M | 60.69M | 581K |
| Total Assets | 230.33M | 196.59M | 310.13M | 238.99M | 122.83M |
| Account Payables | 1.09M | 1.64M | 1.38M | 5.65M | 554K |
| Short-term Debt | 0 | 0 | 0 | 0 | 8.92M |
| Tax Payables | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue | 0 | 0 | 0 | 0 | 0 |
| Other Current Liabilities | 2.96M | 131K | 3.9M | 230K | 4.25M |
| Total Current Liabilities | 5.15M | 7.81M | 12.97M | 27.61M | 30.01M |
| Long-term Debt | 0 | 0 | 27.34M | 29.42M | 22.4M |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue (Non-current) | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Liabilities | 0 | 0 | 2.56M | 0 | 0 |
| Total Non-current Liabilities | 0 | 0 | 30.18M | 29.57M | 22.4M |
| Total Liabilities | 5.15M | 7.81M | 43.15M | 57.18M | 52.4M |
| Common Stock | 4K | 4K | 6K | 6K | 6K |
| Retained Earnings | (127.57M) | (170.43M) | (222.8M) | (325.13M) | (446.46M) |
| Accumulated OCI | (231K) | (751K) | 312K | (48K) | 83K |
| Other Stockholders Equity | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 |
| Total Equity | 225.18M | 188.78M | 266.97M | 181.82M | 70.43M |
| Total Debt | 0 | 105K | 28.49M | 29.7M | 31.31M |
| Net Debt | (122.16M) | (130M) | (38.4M) | (5.93M) | (22.68M) |
Balance Sheet
Assets, liabilities & equity
| Cash & Equivalents | $51.8M |
| Short-term Investments | $76.6M |
| Receivables | $772.0K |
| Other Current | $3.9M |
| Total Current Assets | $133.1M |
| PP&E (Net) | $197.0K |
| Intangible Assets | $24.0K |
| Long-term Investments | $231.0K |
| Other Non-current | $83.0K |
| Total Non-current Assets | $535.0K |
| Total Assets | $133.6M |
Analysis
Selected assets total $133.6M for Latest. The largest visible component is Short-term Investments at $76.6M, about 57.3% of the tab total. Use the mix to judge balance sheet concentration, liquidity, leverage, and how much of book value is supported by tangible operating assets.
Recent Filings
Recent regulatory filings
| Filing | Description | Date | |
|---|---|---|---|
| 8-K | Current report | Sep 16, 2026 | |
| S-8 | S-8 filing | Aug 12, 2026 | |
| 8-K | Current report | Aug 12, 2026 | |
| 10-Q | Quarterly report | Aug 12, 2026 | |
| 4 | Statement of changes in beneficial ownership | Jun 17, 2026 |
How much cash does ABOS have?
Acumen Pharmaceuticals, Inc. (ABOS) reported $53.99M in cash and equivalents in fiscal 2025.
How much debt does ABOS carry?
Acumen Pharmaceuticals, Inc. (ABOS) reported $31.31M of total debt, with net debt of -$22.68M.
Continue the stock analysis
Jump to another research area for this company.